Bio-Rad Laboratories, Inc.
NYSE:BIOMedical - Devices
-$0.65 today
- Market cap
- $9.95B
- Beta
- 1.08
- P/E (TTM)
- 45.4
- EPS (TTM)
- $6.26
Volume 0.46M
Average 0.38M
BIO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Bio-Rad Laboratories, Inc.NYSE: BIO
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow declines year over year
Q2 FY2026 operating cash flow of $98.7M fell 15.3% year over year, behind the -7.8% change in trailing-twelve-month operating cash flow. Sequentially, it fell 8.7% from the prior quarter. Over 3 fiscal years it compounded at +39.9% a year.
Context
- Operating cash flow amounted to 20.6% of revenue in FY2025, up 2.9 pp from a year earlier.
- Operating cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -15.3% toward the trailing-twelve-month pace of -7.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 532.2M USD
- Year-over-year change
- +16.9%
- 4-year CAGR
- -5.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 532.2M | +16.9% |
| FY2024 | 2024-12-31 | 455.2M | +21.4% |
| FY2023 | 2023-12-31 | 374.94M | +92.8% |
| FY2022 | 2022-12-31 | 194.45M | -71.0% |
| FY2021 | 2021-12-31 | 669.46M | — |
Operating Cash Flow vs competitors
How BIO compares with its peers on the latest reported figures
- BIO's LTM Jun 2026 operating cash flow of $492.6M is the 4th largest of the 11 companies compared; the peer median is $162.63M.
- Its year-over-year change of -7.8% is the 8th highest of 11, against a peer median of +8.1%.
- Operating cash flow amounts to 19.0% of revenue for BIO, versus a peer median of 20.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $9.32B | +21.9% | -5.1% | 19.7% | |
| LTM Sep 2026 | $6.86B | +8.6% | -9.0% | 26.8% | |
| LTM Jul 2026 | $628.86M | +7.6% | -5.1% | 21.6% | |
| LTM Jun 2026 | $492.6M | -7.8% | +39.9% | 19.0% | |
| LTM Sep 2026 | $337.6M | +34.4% | +4.7% | 27.5% | |
| LTM Jun 2026 | $190.4M | +14.8% | -21.2% | 5.4% | |
| LTM Jun 2026 | $134.86M | +2.1% | -12.0% | 17.2% | |
| LTM Mar 2026 | $111.84M | -35.9% | -25.0% | 69.9% | |
| LTM Mar 2026 | $90.66M | -18.5% | -5.9% | 105.1% | |
| LTM Sep 2026 | $57.51M | -20.3% | +114.4% | 9.2% | |
| LTM Jun 2026 | $25.26M | +19.4% | — | 12.1% | |
| Peer median (excluding BIO) | $162.63M | +8.1% | -5.9% | 20.6% | |
Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 4.25B | (3.63B) | (637.3M) | (1.84B) | 759.9M |
| Depreciation & Amortization | 137.6M | 137.3M | 145.9M | 151.6M | 165.4M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 51.2M | 60.9M | 61.3M | 62.3M | 58M |
| Change in Working Capital | 1.14B | (1.61B) | (432.8M) | (620.8M) | 272.4M |
| Accounts Receivables | (20.4M) | (87.4M) | 11.4M | 16.2M | 19.6M |
| Inventory | 46.1M | (158.8M) | (46.3M) | 8.5M | 68.9M |
| Accounts Payables | 69.9M | (94.2M) | (51.8M) | (40.9M) | (100K) |
| Other Working Capital | 1.05B | (1.27B) | (346.1M) | (604.6M) | 184M |
| Other Non-Cash Items | (4.92B) | 5.23B | 1.24B | 2.71B | (723.5M) |
| Operating Cash Flow | 669.46M | 194.45M | 374.94M | 455.2M | 532.2M |
| Capital Expenditures | (133.75M) | (114.16M) | (156.68M) | (189M) | (157.6M) |
| Acquisitions (Net) | (125.52M) | (99.39M) | 2.5M | 0 | (218.4M) |
| Purchases of Investments | (851.63M) | (2.06B) | (689.04M) | (1.28B) | (669.3M) |
| Sales of Investments | 766.9M | 1.07B | 863.22M | 1.31B | 62M |
| Other Investing Activities | (453.39M) | (1.21M) | 211K | (23.3M) | 793.6M |
| Investing Cash Flow | (797.38M) | (1.21B) | 20.21M | (160.2M) | (189.7M) |
| Debt Repayment | (3.02M) | 1.19B | (467K) | (400K) | (500K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 15.8M |
| Common Stock Repurchased | (50M) | (215.68M) | (428.73M) | (203.6M) | (295.5M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.41M) | 3.55M | 3.55M | (14.8M) | (3M) |
| Financing Cash Flow | (55.43M) | 973.58M | (425.65M) | (218.8M) | (283.2M) |
| Effect of Forex Changes | (12.64M) | 2.98M | 321K | 9.2M | (19M) |
| Net Change in Cash | (195.98M) | (36.59M) | (30.18M) | 85.4M | 40.3M |
| Free Cash Flow | 535.72M | 80.29M | 218.26M | 266.2M | 374.6M |
Bio-Rad Laboratories, Inc.
NYSE:BIO
Intrinsic Alpha fair value
Locked
Current Price
$370.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.